OVID Ovid Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1636651 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-78.0%
TTM net income YoY-18.7%
TTM EPS YoY—
Revenue 3-yr CAGR69.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,700.3%
Net margin-2,971.3%
FCF margin—
EBITDA margin-4,694.6%
Returns
ROE-35.4%
ROA-30.1%
ROIC (approx.)-52.1%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets10.6%
Debt / equity0.00x
Current ratio11.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.34x
Accruals ratio10.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.25M | $566,000 |
| R&D expense | $25.58M | $36.77M |
| SG&A expense | $24.11M | $25.68M |
| Operating income | -$42.44M | -$61.88M |
| Pretax income | -$17.41M | -$26.43M |
| Income tax | $0 | $0 |
| Net income | -$17.41M | -$26.43M |
| EBITDA | -$42.17M | -$61.27M |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $13.15M | $28.23M |
| Short-term investments | $56.48M | $26.77M |
| Current assets | $74.37M | $55.94M |
| PP&E, net | $252,000 | $433,000 |
| Intangibles | $0 | $100,000 |
| Total assets | $150.93M | $92.17M |
| Current liabilities | $8.29M | $10.52M |
| Total liabilities | $20.27M | $23.94M |
| Shareholders' equity | $130.66M | $68.23M |
| Shares outstanding | 130.18M | 71.01M |
| Cash flow statement | ||
| Operating cash flow | -$38.33M | -$55.96M |
| Capital expenditure | $0 | $71,000 |
| Free cash flow | -$38.33M | -$56.03M |
| Investing cash flow | -$49.85M | $54.59M |
| Financing cash flow | $75.21M | $622,000 |
| Depreciation & amortization | $273,000 | $613,000 |
| Stock-based compensation | $4.81M | $6.28M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.